Randall J. Bateman

51.3k citations

249 papers · 19.5k indexed · 18 hit papers · h-index 57

Co-authors: John C. Morris David M. Holtzman Kwasi G. Mawuenyega Vitaliy Ovod Kevin E. Yarasheski Tom Kasten Ling Y. Munsell Wendy Sigurdson
Topics: Alzheimer's disease research and treatments (164 papers)Dementia and Cognitive Impairment Research (107 papers)Cholinesterase and Neurodegenerative Diseases (23 papers)
Cited by: Biological Psychiatry Physiology Neurology
Journals: Nature Science New England Journal of Medicine
Partner nations: United States United Kingdom Sweden

In The Last Decade

Randall J. Bateman

234 papers receiving 19.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lecanemab in Early Alzheimer’s Disease

2022 2.7k citations Randall J. Bateman et al. profile →
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease

2010 1.6k citations Kwasi G. Mawuenyega, Wendy Sigurdson et al. Science profile →
Alzheimer's disease

2015 1.3k citations Randall J. Bateman, Kaj Blennow et al. profile →
Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle

2009 1.2k citations Miranda M. Lim, Randall J. Bateman et al. Science profile →
Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance

2011 887 citations Jungsu Kim, Bruce W. Patterson et al. profile →
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

2019 551 citations Suzanne E. Schindler, James G. Bollinger et al. profile →
Tau Kinetics in Neurons and the Human Central Nervous System

2018 397 citations Chihiro Sato, Nicolas R. Barthélemy et al. profile →
Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis

2017 386 citations Vitaliy Ovod, Kwasi G. Mawuenyega et al. Alzheimer s & Dementia profile →
Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

2021 267 citations Shorena Janelidze, Henrik Zetterberg et al. JAMA Neurology profile →
Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease

2020 265 citations Nicolas R. Barthélemy, Kanta Horie et al. profile →
Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease

2022 242 citations Shorena Janelidze, Nicolas R. Barthélemy et al. profile →
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study

2022 185 citations Eric McDade, Randall J. Bateman et al. profile →
A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

2021 136 citations Tim West, Kristopher M. Kirmess et al. profile →
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance

2022 127 citations Shorena Janelidze, Nicholas Cullen et al. Alzheimer s & Dementia profile →
Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios

2023 77 citations Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology profile →
Disease staging of Alzheimer’s disease using a CSF-based biomarker model

2024 49 citations Kanta Horie, Nicolas R. Barthélemy et al. Nature Aging profile →
Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive Impairment

2024 42 citations Shorena Janelidze, Nicolas R. Barthélemy et al. JAMA Neurology profile →
Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer’s disease

2025 27 citations Kanta Horie, Shorena Janelidze et al. profile →

Peers

Countries citing papers authored by Randall J. Bateman

Since Specialization

Citations

This map shows the geographic impact of Randall J. Bateman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randall J. Bateman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randall J. Bateman more than expected).

Fields of papers citing papers by Randall J. Bateman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randall J. Bateman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randall J. Bateman. The network helps show where Randall J. Bateman may publish in the future.

Co-authorship network of co-authors of Randall J. Bateman

This figure shows the co-authorship network connecting the top 25 collaborators of Randall J. Bateman. A scholar is included among the top collaborators of Randall J. Bateman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randall J. Bateman. Randall J. Bateman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force 2025 ·The Journal of Prevention of Alzheimer s Disease ·Davide Angioni,Lefkos Middleton,Randall J. Bateman,Paul Aisen,Adam L. Boxer,(unknown),Jing Zhou,Irene Gerlach,Rema Raman,Howard Fillit,Stephen Salloway,Reisa Sperling,Bruno Vellas,(unknown)	2
2	Cognitive reserve influences symptom onset and longitudinal decline in Dominantly Inherited Alzheimer's Disease 2024 ·Alzheimer s & Dementia ·Jorge J. Llibre‐Guerra,Ruijin Lu,Alan E. Renton,Brian A. Gordon,Tammie L.S. Benzinger,Andrew J. Aschenbrenner,Jason J. Hassenstab,Chengjie Xiong,Richard J. Perrin,Laura Ibáñez,Alison Goate,Carlos Cruchaga,John C. Morris,Alisha Daniels,Eric McDade,Randall J. Bateman	0
3	Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology 2024 ·Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring ·Daniel J. Figdore,Heather J. Wiste,Joshua A. Bornhorst,Randall J. Bateman,Yan Li,Jonathan Graff‐Radford,David S. Knopman,Prashanthi Vemuri,Val J. Lowe,Clifford R. Jack,Ronald C. Petersen,Alicia Algeciras‐Schimnich	9
4	Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratiosbreakdown → 2023 ·JAMA Neurology ·Shorena Janelidze,Nicolas R. Barthélemy,Yingxin He,Randall J. Bateman,Oskar Hansson	77
5	Independent study demonstrates amyloid probability score accurately indicates amyloid pathology 2023 ·Annals of Clinical and Translational Neurology ·I. Fogelman,Tim West,Joel B. Braunstein,Philip B. Verghese,Kristopher M. Kirmess,Matthew R. Meyer,John H. Contois,Eli Shobin,Kyle Ferber,(unknown),Carrie E. Rubel,Danielle Graham,Randall J. Bateman,David M. Holtzman,Shuguang Huang,Joanne Yu,Sha Yang,Kevin E. Yarasheski	13
6	Evaluating Regional Importance for Tau Spatial Spread in Predicting Cognitive Impairment with Machine Learning 2023 ·Alzheimer s & Dementia ·(unknown),Austin McCullough,Brian A. Gordon,Charles D. Chen,Nicole S. McKay,Diana A. Hobbs,Sarah Keefe,Shaney Flores,Russ C. Hornbeck,Chengjie Xiong,Jason J. Hassenstab,Randall J. Bateman,Beau M. Ances,John C. Morris,Tammie L.S. Benzinger,(unknown)	1
7	Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease 2023 ·Brain Communications ·Nicholas Cullen,Shorena Janelidze,Erik Stomrud,Randall J. Bateman,Sebastian Palmqvist,Oskar Hansson,Niklas Mattsson	5
8	Human striatal glia differentially contribute to AD- and PD-specific neurodegeneration 2023 ·Nature Aging ·Jinbin Xu,(unknown),Yiran Hou,(unknown),(unknown),Shinnosuke Yamada,(unknown),(unknown),William C. Knight,Randall J. Bateman,Tammie L.S. Benzinger,Jason J. Yi,Qingyun Li,Ting Wang,Joel S. Perlmutter,John C. Morris,Guoyan Zhao	23
9	Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study 2023 ·eLife ·Peter R Millar,Brian A. Gordon,Patrick H. Luckett,Tammie L.S. Benzinger,Carlos Cruchaga,Anne M. Fagan,Jason J. Hassenstab,Richard J. Perrin,Suzanne E. Schindler,Ricardo Allegri,Gregory S. Day,Martin R. Farlow,Hiroshi Mori,(unknown),(unknown),Randall J. Bateman,John C. Morris,Beau M. Ances	31
10	Suvorexant Acutely Decreases Tau Phosphorylation and Aβ in the Human CNS 2023 ·Annals of Neurology ·Brendan P. Lucey,Haiyan Liu,Cristina D. Toedebusch,(unknown),(unknown),(unknown),Kwasi G. Mawuenyega,James G. Bollinger,Vitaliy Ovod,Nicolas R. Barthélemy,Randall J. Bateman	46
11	Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways 2022 ·Communications Biology ·Donald L. Elbert,Bruce W. Patterson,Brendan P. Lucey,Tammie L.S. Benzinger,Randall J. Bateman	39
12	Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers 2021 ·Brain Communications ·Duygu Tosun,Dallas P. Veitch,Paul Aisen,Clifford R. Jack,William J. Jagust,Ronald C. Petersen,Andrew J. Saykin,James Bollinger,Vitaliy Ovod,Kwasi G. Mawuenyega,Randall J. Bateman,Leslie M. Shaw,John Q. Trojanowski,Kaj Blennow,Henrik Zetterberg,Michael W. Weiner	53
13	Regional age-related atrophy after screening for preclinical alzheimer disease 2021 ·Neurobiology of Aging ·(unknown),Pamela LaMontagne,Matthew F. Glasser,Randall J. Bateman,David M. Holtzman,Igor Yakushev,Jasmeer P. Chhatwal,Gregory S. Day,Clifford R. Jack,Catherine J. Mummery,Richard J. Perrin,Brian A. Gordon,John C. Morris,Joshua S. Shimony,Tammie L.S. Benzinger	9
14	Recapitulation of Endogenous 4R Tau Expression and Formation of Insoluble Tau in Directly Reprogrammed Human Neurons 2021 ·SSRN Electronic Journal ·(unknown),Chihiro Sato,Elena Ficulle,Anan Yu,Kanta Horie,Nicolas R. Barthélemy,Susan G. Fox,Celeste M. Karch,Randall J. Bateman,Henry Houlden,Richard I. Morimoto,(unknown),Karen Duff,Andrew S. Yoo	5
15	Sleep Deprivation Affects Tau Phosphorylation in Human Cerebrospinal Fluid 2020 ·Annals of Neurology ·Nicolas R. Barthélemy,Haiyan Liu,William Lu,Paul T. Kotzbauer,Randall J. Bateman,Brendan P. Lucey	84
16	Persistent metabolic youth in the aging female brain 2019 ·Proceedings of the National Academy of Sciences ·Manu S. Goyal,Tyler Blazey,Yi Su,Lars E. Couture,Tony J. Durbin,Randall J. Bateman,Tammie L.S. Benzinger,John C. Morris,Marcus E. Raichle,Andrei G. Vlassenko	108
17	Correction: In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS 2012 ·PLoS ONE ·Kristin R. Wildsmith,Jacob M. Basak,Bruce W. Patterson,(unknown),Jungsu Kim,Kevin E. Yarasheski,(unknown),Kwasi G. Mawuenyega,Hong Jiang,Maia Parsadanian,Hyejin Yoon,Tom Kasten,Wendy Sigurdson,Chengjie Xiong,Alison Goate,David M. Holtzman,Randall J. Bateman	4
18	Decreased Clearance of CNS β-Amyloid in Alzheimer’s Diseasebreakdown → 2010 ·Science ·Kwasi G. Mawuenyega,Wendy Sigurdson,Vitaliy Ovod,Ling Y. Munsell,Tom Kasten,John C. Morris,Kevin E. Yarasheski,Randall J. Bateman	1637
19	Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cyclebreakdown → 2009 ·Science ·(unknown),Miranda M. Lim,Randall J. Bateman,James J. Lee,(unknown),John R. Cirrito,Nobuhiro Fujiki,Seiji Nishino,David M. Holtzman	1152
20	Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism 2006 ·Journal of Neuroscience ·Ke‐Jie Yin,John R. Cirrito,Ping Yan,Xiao Hu,Qingli Xiao,(unknown),Randall J. Bateman,Haowei Song,Fong‐Fu Hsu,John Turk,Jan Xu,Chung Y. Hsu,Jason C. Mills,David M. Holtzman,Jin‐Moo Lee	307

About Randall J. Bateman

Randall J. Bateman is a scholar working on Psychiatry and Mental health, Physiology and Biological Psychiatry, having authored 249 papers that have together received 19.5k indexed citations. Recurring topics across this work include Alzheimer's disease research and treatments (164 papers), Dementia and Cognitive Impairment Research (107 papers) and Cholinesterase and Neurodegenerative Diseases (23 papers). The work is most often cited by research in Biological Psychiatry (1.2k citations), Physiology (12.0k citations) and Neurology (3.6k citations). Randall J. Bateman has collaborated with scholars based in United States, United Kingdom and Sweden. Frequent co-authors include John C. Morris, David M. Holtzman, Kwasi G. Mawuenyega, Vitaliy Ovod, Kevin E. Yarasheski, Tom Kasten, Ling Y. Munsell, Wendy Sigurdson, Kaj Blennow and Reisa A. Sperling. Their work appears in journals such as Nature, Science and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact